US2021186910A1PendingUtilityA1
Medicaments for slowing parkinson's disease
Est. expiryNov 28, 2034(~8.4 yrs left)· nominal 20-yr term from priority
A61K 31/198A61K 31/4439A61K 2300/00A61P 25/16A61K 45/06A61K 31/165A61K 31/00A61P 43/00
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Opicapone, levodopa and an AADC inhibitor are described for use in slowing the progression of Parkinson's Disease.
Claims
exact text as granted — not AI-modified1 - 6 . (canceled)
7 . A method of slowing or delaying progression of Parkinson's Disease which method comprises administering to a patient diagnosed with Parkinson's Disease an effective amount of opicapone without levodopa.
8 - 9 . (canceled)
10 . The method of claim 7 , wherein the slowing of the progression of Parkinson's Disease involves a delay in the progression of Parkinson's Disease by a period of at least one month.
11 . (canceled)
12 . The method of claim 7 , wherein opicapone is administered once a day.
13 . (canceled)
14 . The method of claim 7 , wherein the dose of opicapone is 25 mg to 100 mg.
15 - 20 . (canceled)
21 . The method of claim 7 , wherein the patient benefits by more than 0.25 hr in OFF period.
22 - 41 . (canceled)
42 . The method of claim 7 , wherein the patient has not previously taken a dopamine agonist, a dopamine precursor, a COMT inhibitor, a MAO-B inhibitor, or an anti-cholinergic.
43 . The method of claim 42 , wherein the patient has not previously taken a dopamine precursor, wherein the dopamine precursor is levodopa.Join the waitlist — get patent alerts
Track US2021186910A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.